Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 4/20 | 0.38 |
| ▸ | NPY1R | P25929 | 3/20 | 0.38 |
| ▸ | NPY2R | P49146 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 5/20 | 0.38 |
| ▸ | NOS1 | P29475 | 4/20 | 0.38 |
| ▸ | NOS3 | P29474 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10190380 | 1.00 | DPP7 (0.46) | DPP7GNAI3GNAO1GNAI1ALOX15 | |
| SCHEMBL16421890 | 1.00 | DPP7 (0.46) | DPP7GNAI3GNAO1GNAI1ALOX15 | |
| SCHEMBL10292018 | 0.95 | DPP7 (0.43) | DPP7GNAI3GNAO1GNAI1ALOX15 | |
| SCHEMBL8745865 | 0.95 | DPP7 (0.43) | DPP7GNAI3GNAO1GNAI1ALOX15 | |
| SCHEMBL8214683 | 0.95 | DPP7 (0.43) | DPP7GNAI3GNAO1GNAI1ALOX15 | |
| SCHEMBL8067808 | 0.87 | DPP7 (0.47) | DPP7GNAI3GNAO1GNAI1CYP1A2 | |
| SCHEMBL12278048 | 0.87 | ANPEP (0.37) | DPP7GNAI3GNAO1GNAI1ALOX15 | |
| SCHEMBL13434929 | 0.87 | ANPEP (0.37) | DPP7GNAI3GNAO1GNAI1ALOX15 | |
| SCHEMBL8125131 | 0.87 | ANPEP (0.37) | DPP7GNAI3GNAO1GNAI1ALOX15 | |
| SCHEMBL26431362 | 0.85 | DPP7 (0.49) | DPP7GNAI3GNAO1GNAI1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240010627-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | PEPTIDREAM INC. (JP) | 2024-01-11 | — | — | US | disclosed |
| EP-4276096-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | PeptiDream Inc. (JP) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| WO-2022149610-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | ペプチドリーム株式会社 | 2022-07-14 | — | — | WO | disclosed |
| US-20170304355-A1 | COMPOSITIONS AND METHODS OF USE THEREOF | SYNEDGEN, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170136056-A1 | METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | UNITED STATES GOVERNMENT | 2017-05-18 | — | — | US | disclosed |
| US-20150031610-A1 | DERIVATIZED POLYGLUCOSAMINES FOR DELIVERY OF SMALL MOLECULES, PEPTIDES, AND PROTEINS | SYNEDGEN, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8399635-B2 | Chitosan derivatives to treat animals or optimize animal health | SYNEDGEN, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100137193-A1 | CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH | SYNEDGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136056-A1 | METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | CHIT1, ALG1, DDOST | DPP7 621/4885GNAI3 2126/4885GNAO1 2313/4885 |
| US-20100137193-A1 | CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH | CHIT1, CHIA, ALG1 | DPP7 461/4885GNAI3 3171/4885GNAO1 2924/4885 |
| US-20170304355-A1 | COMPOSITIONS AND METHODS OF USE THEREOF | SI, ENGASE, IDUA | DPP7 302/4885GNAI3 2464/4885GNAO1 1862/4885 |
| US-20150031610-A1 | DERIVATIZED POLYGLUCOSAMINES FOR DELIVERY OF SMALL MOLECULES, PEPTIDES, AND PROTEINS | MUC1, DDOST, EPCAM | DPP7 341/4885GNAI3 628/4885GNAO1 1624/4885 |
| US-20240010627-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | GMPS, MAPT, UROD | DPP7 2455/4885GNAI3 617/4885GNAO1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.